Company Research Report: Becton, Dickinson and Company (BD)

Company Overview

• Name: Becton, Dickinson and Company (BD)

• Mission: Advancing the world of health by improving medical discovery, diagnostics, and the delivery of care.

• Founded: No information is available on the founding year and founder.

• Key People: Tom Polen, CEO; Katie Szyman, President of BD Advanced Patient Monitoring.

• Headquarters: Franklin Lakes, New Jersey, USA.

• Number of Employees: Over 70,000.

• Revenue: No information is available.

• Known For: Developing innovative technology, services, and solutions to advance clinical therapy, diagnostics, and safety in healthcare delivery.

Products

• BD® Hypodermic Syringe and Needle Solutions

• Description: Offers a comprehensive range of hypodermic syringes and needles.

• Key Features:

• Wide selection of high-quality products.

• Reliable, adaptable, and validated for use with most major infusion pump brands.

• Manufactured primarily in the USA for the US market, ensuring reliability and supply continuity.

• Specialized Products:

• BD SafetyGlide™ Needles: With Activation Assist technology for safer injections.

• BD Eclipse™ Needles: Easy to use and cost-effective, needing minimal training.

• BD Integra™ Syringes: Designed to reduce medication waste.

• BD SafetyGlide™ Syringes for TB and Allergy: For delivering small doses safely.

Recent Developments

• New Products Launched:

• Robotics Solution for Single-Cell Research: A collaboration with Hamilton Robotics, featuring BD® OMICS-One XT WTA Assay and the Hamilton® Microlab™ NGS STAR platform for automation in genetic sequencing.

• Acquisitions:

• Advanced Patient Monitoring: Completed acquisition of Edwards Lifesciences' Critical Care product group. The business has been renamed as BD Advanced Patient Monitoring.

• New Features and Technology Updates:

• AI and Machine Learning Integration: Advanced AI-enabled clinical decision tools for BD Advanced Patient Monitoring facilitate integrated monitoring and treatment innovations.

• Partnerships and Alliances:

• Partnership with Hamilton Robotics to innovate and accelerate genomic research processes.

Mergers & Acquisitions

• Approach: Focus on enhancing patient outcomes, reducing care costs, and advancing healthcare safety through strategic acquisitions.

• Recent Transactions:

• Tepha (July 2021): Enhances biomaterial capabilities.

• Parata Systems (July 2022): Expands in pharmacy automation.

• Cytognos (February 2022): Strengthens immunology research capabilities.

• Venclose (December 2021): Increases presence in vascular solutions.

Strategic Objectives

• Differentiated Technologies: Focus on high-growth markets and global reach with digital and connected solutions.

• Environment, Social, and Governance (ESG) Initiatives: Recognized in Bloomberg Gender Equality Index and Fortune's Change the World list.

Conclusion

BD is a leading global medical technology company committed to improving health through innovation in medical devices and solutions. Through strategic acquisitions and product development, BD aims to advance healthcare delivery by addressing critical front-line challenges, leverage technology, and expand access to quality care globally.

Note: Revenue and specific founding details, including year and founder, were not provided in the data.